Endocrinology

Your daily dose of clinical news you may have missed.

The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.

AACE 2023. Deaths among persons with diabetes in the US related to vascular complications increased from 2001 to 2020, primarily driven by renal complications.

The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.

Your daily dose of clinical news you may have missed.

GLP-1 RA side effects such as nausea and vomiting can be minimized by starting at the lowest available dose and titrating slowly; Dr Caroline Apovian explains why.

GLP-1 receptor agonist-based medications for obesity modify gut hormone imbalances, making diet and lifestyle change far more effective, explains Caroline Apovian, MD.

The 2023 algorithm emphasizes a complication-centric approach, beyond glucose levels, for determining first-line pharmacotherapy.

The novel ablation technique which "rejuvenates" critical duodenal mucosa, is followed after 2 weeks by treatment with semaglutide and was both safe and effective.

The American College of Physicians announced an initiative that renews and expands its focus on equitable access to obesity care, including new resources for physicians.

Women with ischemic heart disease who were metabolically unhealthy but fit were more than 50% more likely to experience a major adverse cardiovascular event.

The wearable tubeless insulin delivery device provides a fixed rate of continuous long-acting insulin for 72 hours, requiring no needles or injections.

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.

Higher intake of sugar-sweetened drinks was linked to increased risk of all-cause death and CVD while healthier choices were inversely associated with both, a new study found.

Screening for diabetes by weight will increase diagnoses; weight regain after loss doesn't cancel health benefits; strategy tested to improve RSV detection; and 2 more studies of note.

Your daily dose of clinical news you may have missed.

Among persons with prediabetes who reverted to normoglycemia, only those who remained physically active saw a reduced risk of all-cause death, study authors report.

A new study examines the legacy effects of weight loss on cardiometabolic disease risk factors, finding benefits persist up to 5 years, despite weight regain.

The disproportionate prevalence of undiagnosed diabetes among racial/ethnic minorities in the US begs for a new screening paradigm; this may be the one.

Sanofi is the third key insulin maker to announce reductions in the cost of its products, joining other giants Eli Lilly and Co and Novo Nordisk.

The announcement follows by 2 weeks a similar plan from Eli Lilly to reduce patient costs as the Biden administration touts effects of new laws on drug prices.

Young children using a hybrid closed-loop insulin delivery system spent 12% more time within their target blood glucose range than those who received standard care, according to new research.

Your daily dose of clinical news you may have missed.

ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.